Company profile: SSI Strategy
1.1 - Company Overview
Company description
- Provider of life sciences consulting combining business, medical, clinical, and pharmacovigilance expertise across the product lifecycle, including pre-clinical target identification, regulatory compliance, toxicology and FIH preparation; early development infrastructure and teams; late-stage evidence for regulatory approval, payer acceptance and patient outcomes; commercialization (launch and post-market support); and AI solutions via Metalmind.
Products and services
- Late Development & Submission: SSI Strategy develops regulatory-grade evidence for regulatory approval, payer acceptance, and patient outcomes, architecting submission strategies during late-stage development
- Early Development: SSI Strategy transforms assets into clinical-stage entities by establishing custom-engineered trial infrastructure and multidisciplinary teams for early studies to enable initial clinical execution
- Pre-Clinical: SSI Strategy identifies targets and ensures regulatory-compliant pre-clinical standards, addressing toxicology concerns and preparing assets for First-in-Human trials through targeted risk assessment and readiness planning
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SSI Strategy
Minafin
HQ: France
Website
- Description: Provider of fine chemicals for life sciences and high tech, developing and manufacturing active ingredients, organic intermediates, and specialty chemicals. Offers APIs (patented, generic, HPAPIs), cosmetic and agricultural ingredients, bio-based solvents and fine chemicals, highly reactive chemistry for complex synthesis, process scale-up, high-pressure chemistry, and niche polymers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Minafin company profile →
Orgenesis
HQ: United States
Website
- Description: Provider of point-of-care platforms, technologies, and networks to develop, produce, and distribute advanced cell and gene therapies, including a novel diabetes treatment that converts liver cells into functional insulin-producing cells. Offers POCare Platform, Therapies, Technologies, and a global POCare Network to lower costs and accelerate market access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orgenesis company profile →
Build Clinical
HQ: United States
Website
- Description: Provider of a HIPAA-compliant platform and services to accelerate clinical research patient recruitment, including custom digital ads on search engines, health websites, and social media; study-specific landing pages; pre-screen questionnaires; real-time participant data management; monthly analytics reporting; and 24/7 support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Build Clinical company profile →
Project Farma
HQ: United States
Website
- Description: Provider of healthcare consulting services to pharmaceutical and medical device manufacturers across the supply chain, including GMP-compliant cell and gene therapy facility builds using modular, bioreactor and single-use technologies; business and manufacturing strategy; turnkey capital projects and project management; validation for GMP/GLP/GCP; quality, regulatory and compliance for ISO/GMP; and engineering and automation solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Project Farma company profile →
Locust Walk
HQ: United States
Website
- Description: Provider of strategic partnering and M&A services, facilitating licensing and acquisition deals in the USA, Europe, Japan, and China. Offers capital raising and underwriting, including private placements, IPO advisory, and SPAC advisory. Delivers strategy consulting and analytics for partnering, M&A, and fundraising. Conducts rigorous due diligence via internal committee and external scientific advisory board.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Locust Walk company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SSI Strategy
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SSI Strategy
2.2 - Growth funds investing in similar companies to SSI Strategy
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SSI Strategy
4.2 - Public trading comparable groups for SSI Strategy
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →